Article
Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis.
International immunopharmacology - 1 Dec 2020
Xie Zhenyu, Li Xin, Lun Yu, He Yuzhen, Wu Song, Wang Shiyue, Sun Jianjian, He Yuchen, Xin Shijie, Zhang Jian
Abstract excerpt
BACKGROUND: Tumor mutation burden (TMB) as a prognostic marker for immunotherapy has shown prognostic value in many cancers. However, there is no systematic investigation on TMB in papillary thyroid carcinoma (PTC). METHODS: Based on the somatic mutation data of 487 PTC patients from The Cancer Genome Atlas (TCGA), TMB was calculated, and we classified the samples into high-TMB (H-TMB) and low-TMB (L-TMB) groups....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.